久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Key vaccine in high demand, but supplies short

By LIU ZHIHUA | China Daily | Updated: 2019-07-05 07:08
Share
Share - WeChat
A woman has a 9-valent vaccine shot in Zhengzhou, capital of Henan province. Each year, some 131,500 new cervical cancer cases are reported in China, and about 53,000 patients die from the disease. ZHANG TAO/FOR CHINA DAILY

Once people can acquire the vaccination on a regular basis, the balance between supply and demand will be gradually restored, he said.

According to a report released earlier this year by Horizon Insights, a consultancy in Shanghai, some 300 million Chinese are in the recommended age group for the 2-valent vaccine, 130 million for the 4-valent, and 90 million for the 9-valent. Every year, 8 million people fall into the recommended age group for each vaccine.

Last year, 300,000 people were vaccinated with the 2-valent type, 1.1 million with the 4-valent, and only 100,000 with the 9-valent, resulting in market values of 500 million yuan, 2.7 billion yuan and 400 million yuan, the report said.

About 833,300 doses of the 2-valent vaccine, 3.41 million of the 4-valent and 1.22 million of the 9-valent were released on the market last year, according to the report.

It estimated that the market value for the 2-, 4-and 9-valent vaccines would reach 1 billion yuan, 7.2 billion yuan and 10 billion in times of peak demand.

There will continue to be a shortage of all three types until next year, as the huge demand that exists now cannot be met in a short period, the report said.

Zhao Heng, founder of consulting company Latitude Health, said the shortage could be resolved through increased production and distribution, but as the three types of vaccine are not on the national compulsory vaccination program, it is difficult for the authorities to order pharmaceutical companies to increase supplies.

However, more than a dozen Chinese pharmaceutical companies are developing HPV vaccines ranging from 2-valent to 14-valent, and some have started phase-3 clinical trials while others have only just received approval for such trials, according to the Horizon Insights report.

|<< Previous 1 2 3 4   
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 香蕉成人国产精品免费看网站 | 亚洲国产国产综合一区首页 | 精品日韩欧美 | 日韩免费看片 | 欧美xx一片 | 亚洲精品99久久久久久 | 亚洲欧美日韩在线精品一区二区 | 亚洲高清综合 | 欧美在线a | 亚洲精美视频 | 亚洲精品午夜一区二区在线观看 | 国产在线综合一区二区三区 | 国语精品视频在线观看不卡 | 久久99精品国产免费观看 | 国产精品私人玩物在线观看 | 久久久久久久久久久大尺度免费视频 | 6080伦理久久精品亚洲 | 日本午夜人成免费视频 | 国产一级在线现免费观看 | 亚洲国产高清在线 | 欧美成人伊人十综合色 | 亚洲精品久久久久中文 | 精品视频在线一区 | 韩国欧美一级毛片 | 日韩亚洲一区中文字幕 | 怡红院亚洲红怡院天堂麻豆 | 亚洲人成在线播放网站 | 狠狠色噜狠狠狠狠色综合久 | 欧美一级人与动毛片免费播放 | 久久99国产精品久久99 | 在线观看免费国产 | 国产成人亚洲欧美三区综合 | 免费福利在线看黄网站 | 色婷婷国产精品欧美毛片 | 一区二区三区欧美在线 | 精品久久看 | 久久久久久久国产 | 91网在线 | 欧美成人三级视频 | 国产精品99久久99久久久看片 | 97一级毛片全部免费播放 |